Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests $83
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests $314
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical data sheet

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

 

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cy7.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  2. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  3. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  5. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  6. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  7. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  8. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  9. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  10. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  11. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  12. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  13. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  14. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  15. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  16. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  17. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  18. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  19. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  20. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  21. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  22. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  23. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  24. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  25. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  26. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  27. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  28. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  29. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  30. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  31. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  32. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  33. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  34. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  35. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  36. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  37. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  38. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  39. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  40. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  41. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  42. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  43. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  44. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  45. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  46. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  47. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  48. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  49. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  50. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  51. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  52. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  53. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  54. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  55. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  56. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  57. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  58. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  59. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  60. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  61. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  62. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  63. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  64. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  65. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  66. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  67. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  68. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  69. Ito Y, et al. 2018. Cell. 174:636. PubMed
  70. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  71. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  72. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  73. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  74. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  75. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  76. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  77. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  78. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  79. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  80. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  81. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  82. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  83. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  84. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  85. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  86. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  87. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  88. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  89. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  90. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  91. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  92. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  93. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  94. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  95. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  96. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  97. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  98. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  99. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  100. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  101. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  102. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  103. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  104. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  105. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  106. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  107. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  108. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  109. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  110. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  111. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  112. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use your Zombie dyes for microscopy application?

Zombie dyes that have been tested for microscopy applications in-house will display data on the product webpage. It should be noted that Zombie may not work for dead cell discrimination in every microscopy application, as a complicated point will be to determine the level of Zombie signal that constitutes a dead cell. Another difficulty may be finding the proper plane for microscopy in order to observe the dead cells.

Why can't I fix my cells prior to using Zombie?

The fixation process can contort and alter the membrane of cells, effectively rendering them as dead. Since the ability of Zombie to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie and Annexin V to detect apoptotic cells?

Yes, Zombie can be used with Annexin V to discriminate live, apoptotic, and dead cells. Cells double positive for both Zombie and Annexin V are dead, while Zombie-dim/Annexin V-positive cells are apoptotic. Live cells will be Zombie-low and Annexin V-negative. The advantage to Zombie over PI and 7-AAD is that you can now fix and/or permeabilize the cells to stain for cell surface and intracellular antigens.

Go To Top Version: 5    Revision Date: 05/20/2020

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account